Loading
A phase 1/2 trial of Belzutifan, Zanzalintinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, now recruiting.
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) is a phase 1/2 interventional study registered as NCT07049926 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2025-07-20 and due to reach its primary completion in 2031-10-26. Interventions recorded: Belzutifan, Zanzalintinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zanzalintinib, Merck & Co. (MSD), Renal cell carcinoma.
Shares Zanzalintinib, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/